Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:CRVSOTCMKTS:CVSINASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsCRVSCorvus Pharmaceuticals$3.94-1.1%$3.83$1.75▼$10.00$271.31M0.58827,273 shs313,955 shsCVSICV Sciences$0.04-2.6%$0.03$0.02▼$0.06$6.99M0.6247,223 shs39,340 shsSAVACassava Sciences$2.01$1.93$1.15▼$42.20$97.10M-2.042.93 million shs468,006 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals+3.11%-3.40%-1.24%+33.11%+123.60%CVSICV Sciences+14.20%-2.83%+53.66%+19.62%-31.40%SAVACassava Sciences+8.65%+8.65%-5.63%+58.27%-82.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACRVSCorvus Pharmaceuticals2.5079 of 5 stars3.51.00.00.01.63.30.6CVSICV SciencesN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences4.187 of 5 stars3.33.00.04.72.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/ACRVSCorvus Pharmaceuticals 3.00Buy$15.00281.19% UpsideCVSICV Sciences 0.00N/AN/AN/ASAVACassava Sciences 2.50Moderate Buy$54.502,611.44% UpsideCurrent Analyst Ratings BreakdownLatest SAVA, CVSI, CRVS, and AVEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/ACVSICV Sciences$15.70M0.43N/AN/A$0.01 per share3.68SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ACRVSCorvus Pharmaceuticals-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)CVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/ASAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/6/2025 (Estimated)Latest SAVA, CVSI, CRVS, and AVEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35CRVSCorvus PharmaceuticalsN/A4.904.90CVSICV Sciences0.261.140.30SAVACassava SciencesN/A9.089.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%CRVSCorvus Pharmaceuticals46.64%CVSICV SciencesN/ASAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%CRVSCorvus Pharmaceuticals28.50%CVSICV Sciences3.80%SAVACassava Sciences2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableCRVSCorvus Pharmaceuticals3068.17 million48.74 millionOptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableSAVACassava Sciences3048.31 million47.15 millionOptionableSAVA, CVSI, CRVS, and AVEO HeadlinesRecent News About These CompaniesSAVA - Cassava Sciences Inc Sustainability - MorningstarJuly 2 at 9:19 PM | morningstar.comMCassava Sciences presents poster at TSC 2025 on SimufilamJune 30 at 7:14 PM | msn.comCassava Presents Promising Preclinical Simufilam Data at TSC Alliance MeetingJune 30 at 7:00 AM | globenewswire.comSAVA Stock Price for Cassava Sciences Inc - MorningstarJune 28, 2025 | morningstar.comMWhy cassava could be a great addition to a balanced dietJune 26, 2025 | msn.comTwo Sigma Investments LP Has $1.33 Million Position in Cassava Sciences, Inc. (NASDAQ:SAVA)June 5, 2025 | marketbeat.comCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava partners with Zindi to give African AI developers better toolsMay 15, 2025 | techzim.co.zwTCassava Sciences Inc.May 15, 2025 | barrons.com5 ON YOUR SIDE: Lead levels in cassava flourMay 15, 2025 | kstp.comKCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comCassava Technologies and Zindi collaborate to showcase African A.I. innovationMay 12, 2025 | thezimbabwemail.comTCassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU EcosystemMay 12, 2025 | devdiscourse.comDNew report finds concerning levels of lead in popular cassava itemsMay 12, 2025 | yahoo.comCassava takes next step for African AIMay 12, 2025 | htxt.co.zaHCassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovationMay 12, 2025 | zawya.comZCassava Reports Q1 2025 Financials Results, Provides Business UpdateMay 9, 2025 | finance.yahoo.comZindi Teams Up with Cassava to Spotlight African AI TalentMay 6, 2025 | msn.comZindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovationMay 5, 2025 | msn.comCassava Consciousness from The Tamarind Galaxy part twoMay 1, 2025 | modernghana.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA, CVSI, CRVS, and AVEO Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Corvus Pharmaceuticals NASDAQ:CRVS$3.94 -0.05 (-1.13%) Closing price 02:54 PM EasternExtended Trading$3.96 +0.02 (+0.51%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.CV Sciences OTCMKTS:CVSI$0.04 0.00 (-2.65%) As of 12:42 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Cassava Sciences NASDAQ:SAVA$2.01 0.00 (0.00%) Closing price 03:57 PM EasternExtended Trading$2.01 0.00 (0.00%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.